— Know what they know.
Not Investment Advice

ATRS NASDAQ

Antares Pharma, Inc.
1W: +0.4% 1M: +0.4% 3M: +62.0% 1Y: +37.0% 3Y: +96.8% 5Y: +128.2%
$5.59
Last traded 2022-05-23 — delisted
NASDAQ · Healthcare · Medical - Instruments & Supplies

Balance Sheet Trends

Total Assets
$258M +21.2% ▲
5Y CAGR: +31.2%
Total Liabilities
$82M -12.5% ▼
5Y CAGR: +31.1%
Shareholders Equity
$176M +47.6% ▲
5Y CAGR: +31.2%
Cash & Investments
$67M +26.4% ▲
5Y CAGR: +19.4%
Total Debt
$24M -43.1% ▼
Net Debt
-$42M -280.2% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2017FY2018FY2019FY2020FY2021
— Assets —
Cash$27M$28M$23M$53M$66M
Short-Term Investments$5M$0$23M$0$1M
Cash & ST Investments$32M$28M$46M$53M$67M
Net Receivables$12M$29M$43M$50M$83M
Inventory$9M$11M$16M$18M$12M
Other Current Assets$3M$3M$3M$5M$0
Total Current Assets$56M$71M$108M$127M$162M
Property, Plant & Equip.$16M$15M$21M$29M$26M
Goodwill & Intangibles$2M$2M$2M$9M$19M
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$148K$148K$1M$2M$0
Total Non-Current Assets$19M$17M$24M$86M$78M
Total Assets$74M$88M$133M$213M$258M
— Liabilities —
Accounts Payable$6M$11M$13M$16M$17M
Short-Term Debt$0$3M$1M$17M$4M
Deferred Revenue$3M$1M$2M$4M$4M
Other Current Liabilities$7M$12M$17M$26M$33M
Total Current Liabilities$16M$27M$32M$63M$59M
Long-Term Debt$25M$22M$40M$25M$20M
Other Non-Current Liab.$0$0$5M$6M$3M
Total Non-Current Liabilities$25M$22M$46M$30M$23M
Total Liabilities$41M$49M$78M$93M$82M
— Equity —
Common Stock$2M$2M$2M$2M$2M
Retained Earnings-$270M-$277M-$279M-$223M-$176M
Accumulated OCI-$700K-$703K-$702K-$683K-$685K
Total Stockholders Equity$34M$39M$54M$119M$176M
Total Liabilities & Equity$74M$88M$133M$213M$258M
— Key Metrics —
Total Debt$25M$25M$42M$42M$24M
Net Debt-$2M-$3M$18M-$11M-$42M
Total Investments$5M$0$23M$0$1M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms